Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-25-033059
Filing Date
2025-06-25
Accepted
2025-06-25 20:25:19
Documents
1
Period of Report
2025-06-24

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1750897515.html 4  
1 FORM 4 wk-form4_1750897515.xml 4 3752
  Complete submission text file 0001628280-25-033059.txt   5431
Mailing Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024
Business Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024 310-388-6706
Niagen Bioscience, Inc. (Issuer) CIK: 0001386570 (see all company filings)

EIN.: 262940963 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)

Mailing Address C/O CHROMADEX CORPORATION 10900 WILSHIRE BLVD. STE 600 LOS ANGELES CA 90024
Business Address
Cohen Ann (Reporting) CIK: 0001923843 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37752 | Film No.: 251074832